Dechra Pharmaceuticals PLC — AGM Information 2019

Oct 18, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4314Q

Dechra Pharmaceuticals PLC

18 October 2019

Date: 18 October 2019

Dechra® Pharmaceuticals PLC

Results of Annual General Meeting (AGM)

AGM Meeting Date: 1.00 pm on 18 October 2019

Issued Share Capital at meeting date: 102,810,767

Number of shareholders in attendance: 9

All resolutions were passed on a show of hands.

Details of the proxy voting instructions lodged prior to the AGM are set out below:

Resolution (No. as noted on proxy form)	Total For (1)		Total Against		Withheld (2)
	No. of votes	% of vote	No. of votes	% of vote	No. of votes
Resolution 1: To receive the accounts, the Strategic Report, the Directors' Report and the Auditor's Report	73,600,333	100	1,169	0.00	124,694
Resolution 2: To approve the Directors' Remuneration Report	72,519,866	99.27	533,633	0.73	672,695
Resolution 3: To declare a final dividend	73,723,024	100	3,172	0.00	0
Resolution 4: To elect Lisa Bright	71,027,627	96.34	2,697,283	3.66	1,286
Resolution 5: To re-elect William Anthony Rice	64,700,457	88.18	8,674,437	11.82	351,301
Resolution 6: To re-elect Ian Page	72,894,442	98.87	830,875	1.13	879
Resolution 7: To re-elect Anthony Griffin	72,692,473	98.87	829,706	1.13	204,017
Resolution 8: To re-elect Julian Heslop	72,655,439	98.55	1,069,878	1.45	879
Resolution 9: To re-elect Ishbel Macpherson	72,432,244	98.32	1,238,292	1.68	55,660
Resolution 10: To re-elect Lawson Macartney	72,658,987	98.55	1,066,330	1.45	879
Resolution 11: To re-appoint PricewaterhouseCoopers as external auditor of the Company	73,101,156	99.98	11,756	0.02	613,283
Resolution 12: To authorise the Audit Committee to determine the remuneration of the external auditor	73,723,991	100	2,205	0.00	0
Resolution 13: To authorise the Directors to allot shares to specific limits	69,401,484	94.13	4,324,496	5.87	216
Resolution 14: To disapply the pre-emption rights	73,525,799	99.73	199,168	0.27	1,229
Resolution 15: To disapply additional pre-emption rights	71,956,054	97.60	1,768,826	2.40	1,315
Resolution 16: To authorise the Company to purchase its own shares	72,768,511	99.00	734,677	1.00	223,007
Resolution 17: To call general meetings (other than an AGM) on not less than 14 clear days' notice	72,473,824	98.30	1,252,372	1.70	0
Resolution 18: To adopt New Articles of Association	73,625,816	99.87	99,231	0.13	1,149

Notes

1.   Includes discretionary votes.

2.   A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.

3.   Resolutions 1 to 13 were ordinary resolutions, requiring more than 50% of shareholder votes to be "For" the resolutions.

4.   Resolutions 14 to 18 were special resolutions, requiring more than 75% of shareholder votes to be "For" the resolutions.

5.   Votes tendered in respect of 73,726,196 shares representing 71.71% of the issued share capital.

In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.

For further information, please contact:

Melanie Hall, Company Secretary                           

Telephone number: 01606 814730

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: www.dechra.com.

Trademarks

Trademarks appear throughout this document in italics.  Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGLLFSVIVLTLIA